Email us: firstname.lastname@example.org
First Warning Systems (FWS) has developed a cutting edge wearable body media, early breast tissue abnormalities and breast cancer detection device intended for use as an adjunct to currently accepted screening modalities. Successfully tested with over 500 patients, the FWS solution has a demonstrated 74%+ correlation to the actual state of cancer in all types of breast tissue. The FWS Circadian Biometric Recorder (CBRTM) is applied to the breasts in a bra insert, records thermodynamic metabolic data, gathering metabolic changes in cell activity over a 2 to 12 hour bases. The recording detects abnormal dynamic tissue processes which are indicative of the state of cancer. FWS initial clinical results proven by biopsy were extremely encouraging with an equal-to and improved accuracy rate when compared to the gold stand of mammography. Without utilizing radiation or compression, the FWS CBRTM had optimal successes in those patients who were under the age for mammography screening, or had dense breast tissue, a condition which mammography and ultrasound are both challenged with as a diagnostic modality.
In April of 2013, California will be the 5th state mandating that a physician notify a patient if they have dense breast tissue. Eleven more states, and now the federal government, have similar laws in process today. Thanks to the efforts of an advocacy group of breast cancer survivors, D.E.N.S.E (Density Education National Survivors Network), women will now be informed that their condition interferes with the effectiveness of mammograms to identify tumors in their breasts. With an early diagnosis (Stage 1), survival rate is exceptional at 95%, however the later the diagnosis the lower the survival rate, with only 35% surviving if diagnosed in Stage 3. With the limitation of diagnostic tools such as mammography and ultrasound to detect cancer in dense breasts, another medium of screening must evolve.
First Warning Systems, Inc. 1325 Airmotive Way, Ste 175-L Reno, NV 89502